PDF(Pubmed)
Abstract：
UNASSIGNED: Since 2005, the cardioprotective effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have garnered attention. The cardioprotective effect could be an added benefit to the use of GLP-1 RA. This systematic review and meta-analysis aimed at summarizing observational studies that recruited type 2 diabetes individuals with fewer cardiovascular (CV) events before enrolling in the research.
UNASSIGNED: Systematically, the databases were searched for observational studies reporting compound CV events and deaths in type 2 diabetics without having the risk of cardiovascular diseases (CVDs) compared to other glucose-lowering agents. A meta-analysis was carried out using random effects model to estimate the overall hazard ratio (HR) with a 95% confidence interval (CI). Five studies were found eligible for the systematic review including a total of 64,452 patients receiving either liraglutide (three studies) or exenatide (two studies).
UNASSIGNED: The pooled HR for major adverse cardiac event (MACE) and extended MACE was 0.72 (95% CI: 0.65 - 0.93, I2 = 68%) and 0.93 (95% CI: 0.89 - 0.98, I2 = 29%), respectively. The pooled HR for hospitalization due to heart failure (HHF) and occurrence of HF was 0.84 (95% CI: 0.77 - 0.91, I2 = 79%) and 0.83 (95% CI: 0.75 - 0.94, I2 = 95%), respectively. For stroke, GLP-1 RA was associated with a significant risk reduction of 0.86 (95% CI: 0.75 - 0.98, I2 = 81%). There was no significant myocardial infarction (MI) risk reduction with GLP-1 RA. As for all-cause mortality, the pooled HR for the occurrence of all-cause mortality was 0.82 (95% CI: 0.76 - 0.88, I2 = 0%). The pooled HR for the occurrence of CV death was 0.75 (95% CI: 0.65 - 0.85, I2 = 38%). GLP-1 RA therapy was associated with a significantly low risk of MACE, extended MACE, all-cause mortality, and CV mortality. Except for MACE, the heterogenicity among the studies was low.
UNASSIGNED: We conclude that GLP-1 RA is associated with a low risk of CV events composites and mortality. The findings support the cardioprotective effect of GLP-1 RA.
UNASSIGNED: Systematically, the databases were searched for observational studies reporting compound CV events and deaths in type 2 diabetics without having the risk of cardiovascular diseases (CVDs) compared to other glucose-lowering agents. A meta-analysis was carried out using random effects model to estimate the overall hazard ratio (HR) with a 95% confidence interval (CI). Five studies were found eligible for the systematic review including a total of 64,452 patients receiving either liraglutide (three studies) or exenatide (two studies).
UNASSIGNED: The pooled HR for major adverse cardiac event (MACE) and extended MACE was 0.72 (95% CI: 0.65 - 0.93, I2 = 68%) and 0.93 (95% CI: 0.89 - 0.98, I2 = 29%), respectively. The pooled HR for hospitalization due to heart failure (HHF) and occurrence of HF was 0.84 (95% CI: 0.77 - 0.91, I2 = 79%) and 0.83 (95% CI: 0.75 - 0.94, I2 = 95%), respectively. For stroke, GLP-1 RA was associated with a significant risk reduction of 0.86 (95% CI: 0.75 - 0.98, I2 = 81%). There was no significant myocardial infarction (MI) risk reduction with GLP-1 RA. As for all-cause mortality, the pooled HR for the occurrence of all-cause mortality was 0.82 (95% CI: 0.76 - 0.88, I2 = 0%). The pooled HR for the occurrence of CV death was 0.75 (95% CI: 0.65 - 0.85, I2 = 38%). GLP-1 RA therapy was associated with a significantly low risk of MACE, extended MACE, all-cause mortality, and CV mortality. Except for MACE, the heterogenicity among the studies was low.
UNASSIGNED: We conclude that GLP-1 RA is associated with a low risk of CV events composites and mortality. The findings support the cardioprotective effect of GLP-1 RA.
摘要：
■自2005年以来，胰高血糖素样肽1受体激动剂（GLP-1RA）的心脏保护作用引起了人们的关注。心脏保护作用可能是使用GLP-1RA的额外益处。本系统综述和荟萃分析旨在总结在参加研究之前招募心血管（CV）事件较少的2型糖尿病个体的观察性研究。
■系统，我们在数据库中搜索了报告与其他降糖药相比,无心血管疾病(CVDs)风险的2型糖尿病患者复合CV事件和死亡的观察性研究.使用随机效应模型进行荟萃分析，以95％置信区间（CI）估计总体风险比（HR）。五项研究被发现符合系统评价的条件，包括总共64,452名接受利拉鲁肽（三项研究）或艾塞那肽（两项研究）的患者。
■主要不良心脏事件（MACE）和延长MACE的合并HR分别为0.72（95％CI：0.65-0.93，I2=68％）和0.93（95％CI：0.89-0.98，I2=29％），分别。因心力衰竭（HHF）和HF发生而住院的合并HR为0.84（95％CI：0.77-0.91，I2=79％）和0.83（95％CI：0.75-0.94，I2=95％），分别。对于中风，GLP-1RA与0.86的显著风险降低相关(95%CI:0.75-0.98,I2=81%)。GLP-1RA没有显著降低心肌梗死（MI）风险。至于全因死亡率，全因死亡率的合并HR为0.82(95%CI:0.76~0.88,I2=0%).CV死亡发生的合并HR为0.75（95％CI：0.65-0.85，I2=38％）。GLP-1RA治疗与MACE的低风险相关，扩展MACE，全因死亡率,和CV死亡率。除了MACE,研究之间的异质性较低。
■我们得出结论，GLP-1RA与CV事件复合和死亡率的低风险相关。研究结果支持GLP-1RA的心脏保护作用。
■系统，我们在数据库中搜索了报告与其他降糖药相比,无心血管疾病(CVDs)风险的2型糖尿病患者复合CV事件和死亡的观察性研究.使用随机效应模型进行荟萃分析，以95％置信区间（CI）估计总体风险比（HR）。五项研究被发现符合系统评价的条件，包括总共64,452名接受利拉鲁肽（三项研究）或艾塞那肽（两项研究）的患者。
■主要不良心脏事件（MACE）和延长MACE的合并HR分别为0.72（95％CI：0.65-0.93，I2=68％）和0.93（95％CI：0.89-0.98，I2=29％），分别。因心力衰竭（HHF）和HF发生而住院的合并HR为0.84（95％CI：0.77-0.91，I2=79％）和0.83（95％CI：0.75-0.94，I2=95％），分别。对于中风，GLP-1RA与0.86的显著风险降低相关(95%CI:0.75-0.98,I2=81%)。GLP-1RA没有显著降低心肌梗死（MI）风险。至于全因死亡率，全因死亡率的合并HR为0.82(95%CI:0.76~0.88,I2=0%).CV死亡发生的合并HR为0.75（95％CI：0.65-0.85，I2=38％）。GLP-1RA治疗与MACE的低风险相关，扩展MACE，全因死亡率,和CV死亡率。除了MACE,研究之间的异质性较低。
■我们得出结论，GLP-1RA与CV事件复合和死亡率的低风险相关。研究结果支持GLP-1RA的心脏保护作用。
